The study focused on key pharmacogenomically important genes and variants associated with anti-cancer drug metabolism and response, such as CYP2D6, DPYD, NUDT15, EPAS1, and XRCC1. Findings of the study revealed notable differences in the allelic frequencies for some of these genes in the Sri Lankan population. This evidence concerns the gene XRCC1 and cancer.